Chronic Rhinosinusitis - Pipeline Insight, 2024

This “Chronic Rhinosinusitis - Pipeline Insight, 2024,” report provides comprehensive insights about 6+ companies and 6+ pipeline drugs in Chronic Rhinosinusitis pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Geography Covered

• Global coverage

Chronic Rhinosinusitis Understanding

Chronic Rhinosinusitis: Overview

Chronic rhinosinusitis refers to a condition that lasts at least 12 weeks, despite attempts to treat it, and causes at least two of the following symptoms: Nasal congestion; Mucus discharge from the nose or mucus that drips down the back of the throat; Facial pain, pressure, or fullness; or a decreased sense of smell. Chronic rhinosinusitis is different from the more common form of rhinosinusitis (called acute rhinosinusitis), which is a temporary infection of the sinuses that often occurs following colds. Unlike acute rhinosinusitis, which is usually caused by infection, chronic rhinosinusitis often has more complicated and elusive causes. Infections can certainly contribute to or worsen chronic rhinosinusitis, but people with the chronic condition usually have long-standing inflammation that cannot be explained by infection alone.

Chronic Rhinosinusitis - Pipeline Insight, 2024 report outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Chronic Rhinosinusitis pipeline landscape is provided which includes the disease overview and Chronic Rhinosinusitis treatment guidelines. The assessment part of the report embraces, in depth Chronic Rhinosinusitis commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Chronic Rhinosinusitis collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

Report Highlights

• The companies and academics are working to assess challenges and seek opportunities that could influence Chronic Rhinosinusitis R&D. The therapies under development are focused on novel approaches to treat/improve Chronic Rhinosinusitis.

Chronic Rhinosinusitis Emerging Drugs Chapters

This segment of the Chronic Rhinosinusitis report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

Chronic Rhinosinusitis Emerging Drugs

CBP-201: Connect BiopharmaCBP-201 is a human monoclonal antibody targeting IL-4Ra, which we have observed to have dose-dependent and differentiated pharmacokinetics and pharmacodynamics in an early clinical trial. Preclinical and clinical data demonstrate that dual inhibition of IL-4 and IL-13 dual is required to achieve desired efficacy in Th2-mediated diseases. CBP-201 binds to IL-4Ra in a manner that prevents the receptor from interacting with other receptor subunits that are required for activation of the signaling pathways that ultimately give rise to Th2-mediated diseases, including atopic dermatitis, asthma and nasal polyps. Currently, it is in Phase II stage of clinical trial evaluation to treat Chronic Rhinosinusitis With Nasal Polyps
LYR-210: Lyra TherapeuticsLyra’s lead product candidate, LYR-210, has completed Phase 2 clinical development to treat chronic rhinosinusitis (CRS), an inflammatory disease of the paranasal sinuses. LYR-210 is an anti-inflammatory implantable drug matrix based upon Lyra’s XTreo™ platform designed to elute mometasone furoate consistently and locally to the inflamed mucosal tissue of CRS patients for up to six months from a single treatment. LYR-210 is being developed as an alternative to sinus surgery for CRS patients.

Chronic Rhinosinusitis: Therapeutic Assessment

This segment of the report provides insights about the different Chronic Rhinosinusitis drugs segregated based on following parameters that define the scope of the report, such as:

Major Players in Chronic Rhinosinusitis

There are approx. 6+ key companies which are developing the therapies for Chronic Rhinosinusitis. The companies which have their Chronic Rhinosinusitis drug candidates in the most advanced stage, i.e. phase II include, Lyra Therapeutics.

Phases

This report covers around 6+ products under different phases of clinical development like

• Late stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I) along with the details of
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates

Route of Administration

Chronic Rhinosinusitis pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

• Oral
• Parenteral
• intravenous
• Subcutaneous
• Topical.

Molecule Type

Products have been categorized under various Molecule types such as

• Monoclonal Antibody
• Peptides
• Polymer
• Small molecule
• Gene therapy

Product Type

Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

Chronic Rhinosinusitis: Pipeline Development Activities

The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Chronic Rhinosinusitis therapeutic drugs key players involved in developing key drugs.

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Chronic Rhinosinusitis drugs.

Chronic Rhinosinusitis Report Insights

• Chronic Rhinosinusitis Pipeline Analysis
• Therapeutic Assessment
• Unmet Needs
• Impact of Drugs

Chronic Rhinosinusitis Report Assessment

• Pipeline Product Profiles
• Therapeutic Assessment
• Pipeline Assessment
• Inactive drugs assessment
• Unmet Needs

Key Questions

Current Treatment Scenario and Emerging Therapies:

• How many companies are developing Chronic Rhinosinusitis drugs?
• How many Chronic Rhinosinusitis drugs are developed by each company?
• How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Chronic Rhinosinusitis?
• What are the key collaborations (Industry-Industry, Industry-Academia), Mergers and acquisitions, licensing activities related to the Chronic Rhinosinusitis therapeutics?
• What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
• What are the clinical studies going on for Chronic Rhinosinusitis and their status?
• What are the key designations that have been granted to the emerging drugs?

Key Players

• Connect Biopharma
• Lyra Therapeutics
• Sanotize Research and Development corp.
• Regeneron Pharmaceuticals
• AstraZeneca
• Kyowa Kirin Co., Ltd.
• Keymed Biosciences Co.Ltd
• Pfizer
• GlycoMira Therapeutics

Key Products

• CBP-201
• LYR-210
• Dupilumab
• Tezepelumab
• Benralizumab
• CM310
• PF-06817024

This product will be delivered within 2 business days.